Several brokerages have updated their recommendations and price targets on shares of Ascendis Pharma A/S (NASDAQ: ASND) in the last few weeks:
- 10/26/2026 – Ascendis Pharma A/S was given a new $268.00 price target by Canaccord Genuity Group.
- 10/26/2026 – Ascendis Pharma A/S had its price target lowered by Citigroup from $360.00 to $330.00. They now have a “buy” rating on the stock.
- 10/26/2026 – Ascendis Pharma A/S was upgraded by Canaccord Genuity Group to “hold”.
- 10/15/2026 – Ascendis Pharma A/S is now covered by UBS Group. They set a “buy” rating and a $269.00 price target on the stock.
- 10/13/2026 – Ascendis Pharma A/S had its “hold (c)” rating reaffirmed by Weiss Ratings.
- 10/10/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.
- 9/26/2026 – Ascendis Pharma A/S was downgraded by Wall Street Zen from “buy” to “hold”.
- 9/25/2026 – Ascendis Pharma A/S had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $300.00 price target on the stock.
- 9/16/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by UBS Group. They now have a $344.00 price target on the stock.
- 9/15/2026 – Ascendis Pharma A/S was downgraded by Raymond James Financial from “strong-buy” to “outperform”. They now have a $287.00 price target on the stock.
- 9/10/2026 – Ascendis Pharma A/S was given a new $344.00 price target by HC Wainwright.
- 9/10/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by TD Cowen.
- 9/10/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by BMO Capital Markets.
- 9/1/2026 – Ascendis Pharma A/S had its price target raised by Oppenheimer from $304.00 to $312.00. They now have an “outperform” rating on the stock.
- 9/1/2026 – Ascendis Pharma A/S had its price target lowered by Morgan Stanley from $275.00 to $273.00. They now have an “overweight” rating on the stock.
- 9/1/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by Wedbush. They now have a $327.00 price target on the stock.
- 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Jefferies Financial Group from $333.00 to $330.00. They now have a “buy” rating on the stock.
- 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Stifel Nicolaus from $328.00 to $326.00. They now have a “buy” rating on the stock.
- 8/31/2026 – Ascendis Pharma A/S was given a new $345.00 price target by UBS Group.
- 8/31/2026 – Ascendis Pharma A/S had its price target lowered by Bank of America from $306.00 to $304.00. They now have a “buy” rating on the stock.
Insider Buying and Selling
In other Ascendis Pharma A/S news, Director Jean-Jacques Bienaimé bought 2,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were purchased at an average price of $246.33 per share, for a total transaction of $492,660.00. Following the acquisition, the director owned 2,900 shares in the company, valued at approximately $714,357. This represents a 222.22% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares in the company, valued at $810,570. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 40.00% of the company’s stock.
Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.
Its commercial products include SKYTROFA (lonapegsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.
See Also
- Five stocks we like better than Ascendis Pharma A/S
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
- Plugging In: Vertiv Cashes In On AI Demand
- Visa’s Toll Booth Keeps Collecting, But the Price Is Rising
- Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps Growing
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
